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BACKGROUND: Bevacizumab provides clinical benefit in multiple solid tumours, but is associated with some increase in bleeding risk.
Thrombotic events necessitating therapeutic anticoagulation (TA) are common in cancer. This report describes the safety of
concurrent bevacizumab and TA in three large placebo-controlled clinical studies.
METHODS: Study 1 (metastatic colorectal cancer (mCRC)), study 2 (mCRC), and study 3 (advanced non-small cell lung cancer) were
blinded phase III studies. Eligibility criteria excluded patients on TA. Patients on protocol treatment who developed thrombotic
events requiring TA were permitted to continue bevacizumab or placebo under specified conditions. Adverse events in patients
who received bevacizumab and TA concurrently were assessed using the NCI–CTCAE scale.
RESULTS: While experience is limited, venous thrombotic events were the most common reason for TA initiation in the three studies.
Severe bleeding event rates for patients receiving TA in the bevacizumab-treated groups were similar in frequency to the placebo
groups, ranging from 0 to 8% or 0 to 67 events per 100 patient-years. No severe pulmonary bleeding was reported in any of the
TA-treated populations.
CONCLUSIONS: These data suggest that bevacizumab did not increase the risk of severe bleeding in cancer patients who received TA.
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Bevacizumab is a monoclonal antibody targeting vascular en-
dothelial growth factor, a key regulator of angiogenesis. When
administered with chemotherapy, bevacizumab has been shown to
improve survival, progression-free survival (PFS) and response
rates (RRs) in metastatic colorectal cancer (mCRC) (Hurwitz et al,
2004) and advanced non-small cell lung cancer (NSCLC) (Sandler
et al, 2006). Additional phase II and III studies have reported
statistically and clinically significant improvements in PFS and/or
RR for mCRC (Kabbinavar et al, 2005; Saltz et al, 2008), NSCLC
(Reck et al, 2009), breast cancer (Miller et al, 2007; Fumoleau et al,
2008), renal cell carcinoma (Escudier et al, 2007; Rini et al, 2008),
and glioblastoma multiforme (Vredenburgh et al, 2007).
Bevacizumab use has been associated with an increase in the
risk of bleeding. Although bleeding events involved typically minor
epistaxis and other self-limited mucosal bleeding, severe (grade
X3) bleeding events have also been reported (Hurwitz et al, 2004;
Kabbinavar et al, 2005; Sandler et al, 2006; Escudier et al, 2007;
Miller et al, 2007; Vredenburgh et al, 2007; Fumoleau et al, 2008;
Rini et al, 2008; Saltz et al, 2008; Reck et al, 2009). In NSCLC, a
randomised phase II study of bevacizumab in combination with
carboplatin and paclitaxel reported severe or fatal pulmonary
haemorrhage (PH) in 9% of bevacizumab-treated patients
(Johnson et al, 2004). On review, it was noted that PH occurred
in 4 of 13 patients (31%) with squamous NSCLC histology but in
only 2 of 54 patients (4%) with non-squamous histology. This led
to the exclusion of patients with predominantly squamous cell
histology from subsequent pivotal phase III studies of bevacizumab
in NSCLC. The reported incidences of severe PH in the
bevacizumab-treated groups in two large phase III NSCLC studies
were 1.9 and 1.2% (Sandler et al, 2006; Reck et al, 2009). In NSCLC,
as well as other tumour types, small increases in the incidence
of severe non-pulmonary bleeding have also been reported,
primarily involving the gastrointestinal (GI) and genitourinary
tract, and the central nervous system (CNS) (Johnson et al, 2004;
Sandler et al, 2006).
Life-threatening venous thromboembolic events (VTEs) includ-
ing deep vein thrombosis (DVT) and pulmonary embolism (PE)
are common in cancer patients and represent a leading cause of
morbidity and mortality in outpatients receiving cancer che-
motherapy (Heit et al, 2000; Khorana et al, 2007). Treatment of
VTEs with therapeutic anticoagulation (TA), using unfractionated
or low molecular-weight heparin (LMWH) and/or vitamin K
antagonists, such as warfarin, is the preferred approach for
management (Gitter et al, 1995; Hutten et al, 2000; Deitcher et al,
2006; Lyman et al, 2007). However, bleeding complications
associated with anticoagulation in cancer patients, irrespective of
the anticoagulant used, are more frequent than in non-cancer
patients receiving TAs (Gitter et al, 1995; Palareti et al, 1996;
Hutten et al, 2000; Lee et al, 2003; Deitcher et al, 2006). A study by
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sHutten et al (2000) showed that the rate of major bleeding was
13.3 events per 100 person-years for patients with malignancy,
compared with 0.3 to 1.1 events per 100 patient-years in patients
receiving TA who do not have underlying malignant disease. In the
CLOT study, cancer patients who developed their first DVT were
randomised to LMWH followed by an oral vitamin K antagonist vs
continued LMWH (Lee et al, 2003). Major bleeding, (defined as
bleeding resulting in death, transfusion of X2 units of blood, a
X2.0gdl
–1 fall in haemoglobin, or bleeding in a critical location
(intracranial, intraocular, intraspinal, retroperitoneal, or pericar-
dial)), occurred in 4% of patients receiving the oral vitamin K
antagonist, compared with 6% of patients continuing on LMWH,
after 6 months of anticoagulation. Important risk factors for
severe bleeding on TA include age and comorbidities (Palareti
et al, 1996).
Given the frequency of thromboembolic disease in cancer
patients and the subsequent requirement for TA, it is not un-
expected that many patients being considered for, or actively
receiving, bevacizumab therapy may also require TA treatment.
Currently, there is limited information available about the safety of
combining bevacizumab and TA therapy. We sought to describe
the bleeding risk in patients receiving TA and bevacizumab in a
retrospective analysis of three large, placebo-controlled studies.
MATERIALS AND METHODS
Selection of studies
The three randomised, placebo-controlled clinical trials analysed
in this report each permitted co-administration of study drug
(bevacizumab or placebo) and TA. Of the many trials that have
been conducted for bevacizumab treatment of solid tumour
cancers, as of 31 March 2008, these three trials (two for treatment
of mCRC (Hurwitz et al, 2004; Saltz et al, 2008) and one for NSCLC
(Reck et al, 2009) have provided the most detailed information
on concomitant use of medication, including anticoagulants.
The selection of anticoagulation agents in all three studies was at
the discretion of treating physicians.
Study details
All patients participating in the three trials were enrolled after
providing informed consent. Human investigations were per-
formed after institutional review board approval, in accord with an
assurance approved by the US Department of Health and Human
Services. Details of study design and eligibility have been
previously described (Hurwitz et al, 2004; Saltz et al, 2008; Reck
et al, 2009). Patients with a recent history (6 months to 1 year) of
cardiovascular disease were excluded from the trials, as were those
treated with TA at baseline.
Patients in all three studies provided written informed consent
according to federal and institutional guidelines before study
procedures began. Human investigations were performed after
ethical approval by a human investigations committee and in
accordance with an assurance filed with and approved by the
Department of Health and Human Services.
Study 1. In this study, 789 patients with previously untreated
CRC, received irinotecan, leucovorin, fluorouracil chemotherapy
plus bevacizumab or placebo (5mgkg
–1 every 2 weeks) (Hurwitz
et al, 2004). In the original protocol, current or recent (within
10 days before day 0) use of full-dose oral or parenteral
anticoagulants was not permitted at study entry, and patients
who developed a thrombotic event requiring TA were discontinued
from study therapy. Persistent (X3 weeks) grade 3 or 4 AEs, or any
significant AE that compromised the subject’s ability to participate
in the study, were also cause for study discontinuation. However,
as some patients were judged by the respective investigators to
have benefited from study treatment, protocol exceptions were
granted to permit resumption of study treatment after TA,
provided there were no additional risk factors for bleeding. An
analysis of bleeding event rates in those patients showed no excess
bleeding risk, and the study was amended to allow continued
participation on TA if the patient had not been unblinded. Study 1
was conducted predominantly in the United States, between 2000
and 2003.
Study 2. This was a 2 2 factorial, randomised, multi-centre,
multi-national phase III study, with four treatment arms
(FOLFOXþbevacizumab (5mgkg
–1 every 2 weeks), FOLFOXþ
placebo, XELOXþbevacizumab (7.5mgkg
–1 every 3 weeks), and
XELOXþplacebo) (Saltz et al, 2008), in which 1369 patients with
inoperable mCRC, who had not previously received systemic
treatment for metastatic disease, were treated with bevacizumab or
placebo. Study 2 was conducted predominantly outside the United
States between 2004 and 2005. Patients with current or recent use
of anticoagulants (within 10 days before study treatment) were
excluded from study entry, except where anticoagulants were used
for maintenance of preexisting IV catheters. Standard discontinua-
tion criteria applied in this study: investigators could also
withdraw patients from the study in the event of intercurrent
illness, AEs, treatment failure, protocol violations, administrative
reasons, or other reasons.
Study 3. Patients with inoperable stage IIIb, IV, or recurrent non-
squamous NSCLC (N¼1043) were treated with gemcitabine/
cisplatin first-line chemotherapy plus bevacizumab or placebo
(Reck et al, 2009). Two bevacizumab doses were tested, 7.5 and
15mgkg
–1, every 3 weeks, and were pooled for this analysis. Study
3 was conducted exclusively outside of the United States, between
2005 and 2006. Patients with current or recent therapeutic use of
full-dose anticoagulants or thrombolytic agents (within 10 days
before study treatment) were excluded from the study. Standard
study discontinuation criteria were described in the study protocol
(see Study 2 above).
Data collection on TA and adverse events
Patients in this report were identified as those receiving an
anticoagulant medication concurrently with study drug following
a VTE during the study. Patients permitted to continue on
bevacizumab and TA were required to have no evidence of
haemorrhage during study; were required to be on 2–3 weeks of
TA, with INR within target range for warfarin and on a stable dose
of anticoagulant; and, for studies 1 and 2, did not have any
evidence of tumour invading or abutting major blood vessels, by
CT scan. All studies excluded patients requiring TA or aspirin
4325mgday
–1 at study entry and patients with known bleeding
diathesis. None of the studies collected specific information
regarding dosage, frequency, or duration of anticoagulant agent,
and only study 3 collected information about anticoagulant
indication (prophylactic or therapeutic). Patients who experienced
a VTE were permitted to resume bevacizumab or placebo after TA
was established with a stable dose of an anticoagulant. Those who
developed arterial thrombosis were required to discontinue
bevacizumab/placebo treatment. None of the studies permitted
crossover to bevacizumab from the placebo group.
Adverse events, including bleeding severity, were assessed using
the NCI–CTCAE scale (version 2.0 for study 1; version 3.0 for
studies 2 and 3) (Trotti et al, 2000, 2003). Information on bleeding
AEs of all grades was collected in studies 2 and 3. In study 1,
however, information on all grades of AEs was only collected
until a pre-planned safety interim analysis, after approximately
one-third of the total sample size was enrolled; after this point,
only grade X3 AE’s were collected. NCI–CTC grade X3 events
are defined as severe adverse events (SAEs). Thrombotic
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definition, DVT and PE requiring anticoagulation are defined as
grade 3 or 4, and are therefore reported for all patients in study 1.
All patients who received TA and study treatment concurrently,
following a treatment emergent VTE, were included in this
analysis. Treatment emergent VTE was defined as VTE with onset
on or after the start of protocol treatment.
In study 1, AEs were collected for 14 days after the final dose of
study drug during first-line therapy. For patients who went on to
receive BV as second-line therapy as a single agent or in
combination with chemotherapy, the serious AEs were collected
at cycle day 0, 7, 14, 21, 28 and 35. The other two studies collected
information on AEs up to 28 days after each patient ended the
study medication.
All bleeding SAEs were individually reviewed, with the incidence
defined by the number of patients with at least one AE as
indicated, and by highest grade as indicated. The number of
person-years of observation is defined as the sum of the time from
the first day on which TA was received following a VTE to the date
of the first bleeding AE that occurred after first use of anti-
coagulant medication. Patients without a bleeding event after
anticoagulant use were censored at the last date of TA or study
drug use, whichever occurred first.
RESULTS
Thrombotic adverse events and treatment
Treatment emergent grades 3–4 VTEs occurred at rates ranging
between 5.0 and 15.3% in the placebo- and bevacizumab-treated
groups in the three studies (Table 1). The incidence of these events
in each study was no higher for patients receiving bevacizumab
than for those receiving control.
Anticoagulation agents
In study 1, warfarin was the TA used by the vast majority (B95%)
of patients who received TA while on study drug. In study 2,
B40% of patients who received TA while on study drug used
warfarin and the remainder used LMWH. In study 3, B35% of
patients receiving TA while on study drug received warfarin, with
the remainder using LMWH.
Study treatment status following start of TA
There were a total of 194 patients in the three trials who received
concurrent study treatment and TA treatment.
In study 1, of the 64 patients in the bevacizumab group who
received TA for thrombosis, 53 (83%) continued TA and study
treatment concomitantly for a median of 27 weeks. Of the
55 patients in the placebo group who started TA for a thrombotic
event, 30 (55%) continued TA and study treatment for a median of
19 weeks (Figure 1).
In study 2, of the 73 patients in the bevacizumab-containing
group who received anticoagulation treatment following a treat-
ment emergent VTE event, 34 (47%) continued study treatment
and concurrent anticoagulants for a median of 14 weeks (Figure 1).
Of the 43 patients in the placebo group who received anti-
coagulation treatment following a VTE event, 28 (65%) continued
study treatment and concurrent anticoagulants for a median of
19 weeks.
In study 3, of the 58 bevacizumab-treated patients who started
TA for a thrombotic event, 36 (62%) continued study treatment
plus concurrent TA for a median of 8 weeks (Figure 1). Of the
27 patients in the placebo group who began TA, 13 (48%)
continued study treatment þ TA for a median of 2 weeks.
Bleeding adverse events in the TA-treated population
In the three studies analysed in this report, the overall rates of
severe bleeding for all patients in the control vs the bevacizumab
groups were: 2.5 vs 3.3% in study 1, 1.2 vs 1.9% in study 2, and 1.2
vs 3.5% in study 3, consistent with the small increase in risk
typically reported in controlled bevacizumab studies. The rates of
all bleeding events (any grade) in patients on TA were assessed in
studies 2 and 3 (Table 2). Rates of severe (grade X3) bleeding
events were assessed for all three studies (Table 2), and were
similar among the control/placebo- and bevacizumab-treated
groups: 7 vs 4% in study 1, 0 vs 3% in study 2, and 8 vs 6% in
study 3, respectively (Table 2). There were three severe bleeding
events in the placebo groups (GI bleeding, CNS bleeding, and
bleeding not otherwise specified) and five in the bevacizumab
groups (rectal bleeding, retroperitoneal bleeding, CNS bleeding,
and two epistaxis events). Among the eight patients who
experienced severe bleeding on TA, two patients, both of whom
received bevacizumab, had concomitant thrombocytopenia (grade
1 thrombocytopenia in study 1, grade 4 thrombocytopenia in study
3). The estimated overall risk of severe bleeding was 4.1% in the
pooled bevacizumab group, and 4.2% in the pooled control group.
As bevacizumab provided significant improvement in time to
disease progression in all of these studies, we corrected for
differences in both time to bleeding event and overall observation
time by calculating rates of severe (gradeX3) bleeding events per
100 person-years. These rates, ranging from 0 to 67 events per 100
person-years, were similar for control and bevacizumab groups. By
Table 1 Overall incidence of thrombotic and bleeding adverse events (treated patients)
Study 1 (mCRC)
a Study 2 (mCRC) Study 3 (NSCLC)
b
Adverse event
IFL/placebo
(n¼397)
IFL/BV
(n¼392)
FOLFOX-4/XELOX/
placebo (n¼675)
FOLFOX-4/XELOX/
BV (N¼694)
CG/placebo
(n¼327)
CG/BV
(n¼659)
b
Patients with any grade events, n (%)
Arterial thrombosis 5 (1.3) 14 (3.6) 10 (1.5) 17 (2.4) 18 (5.5) 25 (3.8)
Venous thrombosis 62 (15.6) 68 (17.3) 65 (9.6) 94 (13.5) 35 (10.7) 85 (12.9)
Bleeding/haemorrhage NA
a NA
a 175 (25.9) 212 (30.5) 67 (20.5) 239 (36.3)
Patients with grade 3/4 events, n (%)
Venous thrombosis 55 (13.8) 60 (15.3) 34 (5.0) 56 (8.1) 21 (6.4) 47 (7.1)
Deep vein thrombosis 27 (6.8) 35 (8.9) 10 (1.5) 21 (3.0) 5 (1.5) 13 (2.0)
Pulmonary embolus 20 (5.0) 15 (3.8) 7 (1.0) 18 (2.6) 10 (3.1) 26 (3.9)
Bleeding/haemorrhage 10 (2.5) 13 (3.3) 8 (1.2) 13 (1.9) 4 (1.2) 23 (3.5)
Abbreviations: BV¼bevacizumab; CG¼cisplatin+gemcitabine; FOLFOX-4¼oxaliplatin, folinic acid and 5-fluorouracil; IFL¼irinotecan/5-fluorouracil/leukovorin;
mCRC¼metastatic colorectal cancer; NA¼not applicable; NSCLC¼non-small cell lung cancer; XELOX¼capecitabine plus oxaliplatin.
aIn study 1, only grades
3–4 bleeding events were uniformly collected.
bThe bevacizumab dose groups in study 3 (7.5 and 15mgkg
–1 every 3 weeks) were pooled.
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three studies, the estimated overall risk of severe bleeding was 9.0
per 100 patient-years in the pooled bevacizumab group, and 10.5
per 100 patient-years in the pooled control group.
There were no reports of severe (grade X3) PH among any
TA-treated patients in the bevacizumab treatment groups in these
studies. No fatal bleeding events occurred in any TA-treated patient.
DISCUSSION
In patients with advanced cancer, thrombosis is a common event
and a major source of morbidity and mortality. The standard
treatment for significant thrombosis is TA, typically starting with
heparinoids, such as unfractionated or LMWH, followed by oral
vitamin K antagonists or continued heparinoids. Unfortunately,
anticoagulation therapy in both cancer and non-cancer popula-
tions is often complicated by major bleeding (Gitter et al, 1995;
Palareti et al, 1996; Hutten et al, 2000; Lee et al, 2003; Deitcher
et al, 2006). Nevertheless, the risk–benefit assessment for TA
usually favours its use because of the immediate life-threatening
consequences of thrombosis.
Bevacizumab has been associated with an increased risk of
bleeding of all grades, although most bleeding events are mild,
self-limited, and frequently mucosal without need for medical
intervention or bevacizumab discontinuation (Hurwitz et al, 2004;
Kabbinavar et al, 2005; Sandler et al, 2006; Escudier et al, 2007;
Miller et al, 2007; Vredenburgh et al, 2007; Fumoleau et al, 2008;
Rini et al, 2008; Saltz et al, 2008; Reck et al, 2009). An increased
risk of severe (grade X3) bleeding has also been reported with
bevacizumab treatment. Severe bleeding has occurred at primary
sites of malignant disease, such as PH in NSCLC patients and
GI bleeding in CRC patients. However, severe bleeding has also
been described at sites not primarily involved with cancer, such
as GI bleeding in patients without CRC, and CNS bleeding in
patients without known brain metastases (Johnson et al, 2004;
Sandler et al, 2006).
The bleeding rates reported in this analysis compare favourably
with bleeding risks reported in the literature for cancer patients
receiving TA (approximately 13 major bleeding events per 100
patient-years) (Hutten et al, 2000). The number of TA patients
with severe bleeding events in the three studies analysed in this
report precluded a definitive analysis of the relative safety of
warfarin vs LMWH in combination with bevacizumab. Of the five
Study 1 (mCRC)
Patients with treatment
emergent VTE
N=130
Study 2 (mCRC)
Patients with treatment
emergent VTE
N=159
Study 3 (NSCLC)
Patients with treatment
emergent VTE
N=120
Used TA
BV arm: n=64
Control arm: n=55
Used TA
BV arm: n=73
Control arm: n=43
Used TA
BV arm: n=58
Control arm: n=27
Did not use TA
n=11
Did not use TA
n=43
Did not use TA
n=35
Discontinued study
treatment
BV arm: n=22
Control arm: n=14
Discontinued study
treatment
BV arm: n=39
Control arm: n=15
Discontinued study
treatment
BV arm: n=11
Control arm: n=25
Continued study
treatment
BV arm: n=36
Control arm: n=13
Continued study
treatment
BV arm: n=34
Control arm: n=28
Continued study
treatment
BV arm: n=53
Control arm: n=30
Figure 1 Study flow charts for patients with treatment emergent VTE.
Table 2 Incidence of bleeding AEs in patients receiving TA and concurrent study treatment
a
Study 1 (mCRC)
b Study 2 (mCRC) Study 3 (NSCLC)
c Pooled studies
d
Study 1 (mCRC)
b
Placebo (n¼30)
IFL/placebo
(n¼30)
IFL/BV
(n¼53)
FOLFOX-4/
XELOX/placebo
(n¼28)
FOLFOX-4/
XELOX/
BV(N¼34)
CG/placebo
(n¼13)
CG/BV
(n¼36)
Pooled placebo
groups (n¼71)
Pooled
bevacizumab
groups (n¼123)
Patients with bleeding AEs n(%)
All grades NA
b NA
b 9 (32) 11 (32) 5 (38) 12 (33) 14 (34) 23 (33)
Epistaxis NA
b NA
b 6 (21) 10 (29) 2 (15) 11 (31) 8 (20) 21 (30)
Pulmonary haemorrhage/
haemoptysis
NA
b NA
b 0 1 (2.9) 1 (8) 1 (3) 1 (2) 2 (3)
Other AEs NA
b NA
b 7 (25)
e 4 (12)
e 3 (23)
f 3 (8)
f 10 (24) 7 (10)
Grades 3–4
g 2 (7) 2 (4) 0 1 (3) 1 (8) 2 (6) 3 (4) 5 (4)
Epistaxis 0 0 0 0 0 2 (6) 0 2 (2)
Pulmonary haemorrhage/
haemoptysis
00 0 0 0 0 0 0
GI bleeding 1 (3) 0 0 0 0 0 1 (1) 0
CNS bleeding 0 1 (2) 0 0 1 (8) 0 1 (1) 1 (1)
Other grades 3–4 AEs
h 1 (3) 1 (2) 0 1 (3) 0 0 1 (1) 2 (2)
Rate of severe (grade X3)
bleeding per 100 persons-years
13 6 0 9 67 20 10.5 9.0
Abbreviations: AE¼adverse event; BV¼bevacizumab; CG¼cisplatin+gemcitabine; CNS¼central nervous system; FOLFOX-4¼oxaliplatin, folinic acid, 5-fluorouracil;
GI¼gastrointestinal; IFL¼irinotecan+5-fluorouracil+leukovoran; mCRC¼metastatic colorectal cancer; NA¼not applicable; NSCLC¼non-small cell lung cancer;
TA¼therapeutic anticoagulation; XELOX¼capecitabine+oxaliplatin.
aFor patients with more than one event of the same type, the highest grade event is reported.
bOnly
severe bleeding events were captured in study 1 (grades 3–4).
cThe bevacizumab dose groups in study 3 (7.5 and 15mgkg
–1every 3 weeks) were pooled in this analysis.
dThe
pooled studies analysis includes studies 2 and 3 for all grade bleeding, and studies 1–3 for grades 3–5 bleeding.
eThe other bleeding events in the study 2 placebo cohort were:
one grade 2 haematuria, two grade 1 gingival bleeding events, and one each of grade 1 rectal haemorrhage, urinary tract haemorrhage, haemorrhoidal haemorrhage and melaena.
The other bleeding events in the cohort that received bevacizumab were: two Grade 1 haematuria events, a grade 3 rectal haemorrhage and a grade 1 rectal haemorrhage.
fThe
other bleeding events in study 3 were two petechiae events (one patient in each treatment cohort), two GI bleeds (one in each cohort) and two CNS bleeds (one in each
cohort).
gNo grade 5 AEs were observed among TA-treated patients in these studies.
hThe other grades 3–4 bleeding events in study 1 were grade 3 haemorrhage (not
otherwise specified) in the IFL/placebo cohort and grade 3 retroperitoneal haemorrhage in the IFL/BV group. In study 2, there was a grade 3 rectal haemorrhage in the cohort
that received bevacizumab.
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spatients receiving concurrent therapy and experiencing a severe
bleeding event in the combined bevacizumab-containing groups,
two were receiving heparin and three were receiving warfarin.
Given the uncommon, but potentially life-threatening compli-
cation of severe PH in patients with NSCLC receiving bevacizu-
mab, the use of anticoagulation in study 3 is of particular interest.
Of the eight grade X3 PH events reported among bevacizumab-
treated patients (Reck et al, 2009), no PH events were reported in
patients receiving TA. Although the number of TA patients in
study 3 was relatively small, these findings are reassuring
regarding the concomitant use of anticoagulants and bevacizumab
in NSCLC.
It should be noted that these analyses were conducted for the
subset of patients experiencing a VTE event in these studies. In
addition, the study population needed to meet baseline eligibility
criteria, which excluded many conditions that may increase
bleeding risks. The proportion of patients continuing on study
drug and TA following a VTE ranged from 47 to 83%. The reasons
that investigators chose to either not initiate TA following a VTE
or to not continue study drug therapy following TA were not
captured. Possible reasons include: that these patients may have
had clinical contraindications to TA, patients could not be
successfully anticoagulated, patients showed signs of clinical
progression, and/or patients were too ill to continue on study
drug therapy. A further limitation of this analysis is that data on
the level, frequency, and duration of anticoagulation was not
routinely collected in these three studies, and that duration on
anticoagulation was relatively short in the NSCLC trial (Reck et al,
2009). In addition, dosing information was not always collected for
LMWH and other anticoagulants. Therefore, the influence of these
factors on bleeding incidence cannot be assessed. The power of
this study is also limited by the numbers of patients, the relatively
low numbers of bleeding events, and the high rate of discontinua-
tion for patients who developed VTE and received TA. Other
studies that included TA for patients treated with bevacizumab
could not be analysed in this report, because detailed information
about use of anticoagulants was not collected in these other
studies. These caveats should be taken into account when
attempting to extrapolate these findings broadly.
Analyses from distinct data sets have evaluated the risks of
anticoagulation and appear to confirm the relative safety of
concurrently administering TA and bevacizumab in cancer
patients. BRiTE, a large observational cohort study for mCRC
patients receiving bevacizumab-based therapy, enrolled 1953
patients, primarily in the community setting, with 133 (6.8%)
receiving concomitant TA at some point during their treatment
course (Grothey et al, 2008). The observed rate of severe bleeding
in this group of patients was 6.0% (Flynn et al, 2008). This estimate of
risk is consistent with the results of this report and also consistent
with the incidence of severe bleeding in on TA who are cancer
patients not receiving bevacizumab. In addition, results from a large
randomised study evaluating bevacizumab in high-grade glioma have
recently been reported. Of the 163 patients enrolled and treated with
bevacizumab, 48 (29.4%) received concomitant TA, and 2 (4%) of
these patients experienced a severe bleeding event (1 patient had
grade 3 menorrhagia and another developed grade 3 tumour-
associated CNS haemorrhage) (Friedman et al, 2009).
In the phase IV international SAiL study of bevacizumab in 1065
NSCLC patients, there were a total of 19 bleeding events in 15 of 87
patients (17.2%; none grade X3) receiving anticoagulants (mostly
LMWH) at baseline, compared with 227 bleeding events in 181
patients (17.0%) for the entire treated population (Griesinger et al,
2008). Although 15% of patients received concomitant anticoagula-
tion therapy at some point during SAiL, the overall incidence of grade
X3 bleeding was low (4%) (Crino et al, 2010). These data suggested
that concomitant use of anticoagulation and bevacizumab-based
therapy was feasible and did not substantially increase the risk of
clinically significant bleeding in NSCLC. Preliminary results from the
bevacizumab treatment registry ARIES have shown no incidence of
PH among 65 patients with NSCLC on TA; future analyses from this
registry will assess the overall bleeding risks for patients on TA
(Kumar et al, 2010).
Bevacizumab is an important therapeutic option for many
patients with common malignancies who will frequently require
TA. This report provides important information to clinicians for
assessing individual risk–benefit decisions for patients requiring
TA in the setting of bevacizumab-containing therapy. Although
experience is limited, these results suggest that combining
bevacizumab with TA does not appreciably increase the risk of
bleeding above the risk of bleeding expected from TA alone.
ACKNOWLEDGEMENTS
We would like to thank the patients who participated in these
trials. At Genentech, we are grateful to Robert Mass, MD, Willis
Navarro, MD, Frank Scappaticci, MD, PhD, and Leonardo Faoro,
MD, for support and advice with paper development, to Coen
Bernaards, PhD, for biostatistical support, and to Abie Craiu, PhD,
for assistance with manuscript preparation. ClinicalTrials.gov
Identifiers: NCT00806923, NCT00062426.
REFERENCES
Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N,
Stroiakovski D, Thatcher N, Tsai C-M, Wu YI, Zhou C (2010) Safety
and efficacy of first-line bevacizumab-based therapy in advanced non-
squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
Lancet Oncol 11(8): 733–740
Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J (2006)
Secondary prevention of venous thromboembolic events in patients
with active cancer: enoxaparin alone versus initial enoxaparin followed
by warfarin for a 180-day period. Clin Appl Thromb Hemost 12(4):
389–396
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C,
Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO,
Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus
interferon alfa-2a for treatment of metastatic renal cell carcinoma: a
randomised, double-blind phase III trial. Lancet 370(9605): 2103–2111
Flynn P, Sugrue M, Feng S, Purdie DM, Grothey A, Sargent DJ, Berlin JD,
Kabbinavar FF, Dong W, Kozloff MF (2008) Incidence of serious
bleeding events (sBE) in patients (pts) with metastatic colorectal cancer
(mCRC) receiving bevacizumab (BV) as part of a first-line regimen:
results from the BRiTE observational cohort study (OCS). J Clin Oncol
20(suppl); abstr 4104
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE,
Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J,
Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in
combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:
4733–4740
Fumoleau P, Greil R, Rayson D, Miller V, Barni S, Aleknavicius E, Tellez E,
Wilson C, Miles DW (2008) Bevacizumab (BV) maintenance therapy
significantly delays disease progression (PD) or death compared with
placebo (PL) in the AVADO trial (BV+docetaxel [D] vs D+PL in 1st-line
HER2-negative locally recurrent [LR] or metastatic breast cancer
[mBC]). Clin Cancer Res 69: abstr 903
Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD (1995)
Bleeding and thromboembolism during anticoagulant therapy: a
population-based study in Rochester, Minnesota. Mayo Clin Proc
70(8): 725–733
Griesinger F, Laskin JJ, Pavlakis N (2008) Safety of first-line bevacizumab-
based therapy with concomitant cardiovascular or anticoagulation
Bevacizumab safety in patients on full-dose anticoagulation
N Leighl et al
417
British Journal of Cancer (2011) 104(3), 413–418 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
smedication in advanced or recurrent non-squamous non-small cell lung
cancer (NSCLC) in MO19390 (SAiL). J Clin Oncol 20(suppl); abstr 8049
Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E,
Kozloff M (2008) Bevacizumab beyond first progression is associated with
prolonged overall survival in metastatic colorectal cancer: results from a
large observational cohort study (BRiTE). J Clin Oncol 33: 5326–5334
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O0Fallon WM, Melton III
LJ (2000) Risk factors for deep vein thrombosis and pulmonary
embolism: a population-based case-control study. Arch Intern Med
160(6): 809–815
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J,
Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G,
Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J
Med 350(23): 2335–2342
Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR (2000)
Incidence of recurrent thromboembolic and bleeding complications
among patients with venous thromboembolism in relation to both
malignancy and achieved international normalized ratio: a retrospective
analysis. J Clin Oncol 18(17): 3078–3083
Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ,
Jablons DM, Langer CJ, DeVore III RF, Gaudreault J, Damico LA,
Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing
bevacizumab plus carboplatin and paclitaxel with carboplatin and
paclitaxel alone in previously untreated locally advanced or metastatic
non-small-cell lung cancer. J Clin Oncol 22(11): 2184–2191
Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R,
Perrou B, Nelson B, Novotny WF (2005) Addition of bevacizumab to
bolus fluorouracil and leucovorin in first-line metastatic colorectal
cancer: Results of a randomized phase II trial. J Clin Oncol 23: 3697–3705
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007)
Thromboembolism is a leading cause of death in cancer patients
receiving outpatient chemotherapy. J Thromb Haemost 5(3): 632–634
Kumar P, Fischbach NA, Brahmer JR, Spigel DR, Beatty S, Teng S, Flick ED,
Sing A, Lynch TJ (2010) Baseline radiographic characteristics and severe
pulmonary hemorrhage in bevacizumab-treated non-small cell lung
cancer patients: Results from ARIES, an observational cohort study
(OCS). J Clin Oncol 28 15s(Suppl); abstr 7619
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M Rickles FR,
Julian JA, Haley S, Kovacs MJ, Gent M (2003) Low-molecular-weight
heparin versus a coumarin for the prevention of recurrent venous
thromboembolism in patients with cancer. N Engl J Med 349(2): 146–153
Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C,
Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson
D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW (2007)
American Society of Clinical Oncology guideline: recommendations for
venous thromboembolism prophylaxis and treatment in patients with
cancer. J Clin Oncol 25(34): 5490–5505
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T,
Cell D, Davidson NE (2007) Paclitaxel plus bevacizumab versus
paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):
2666–2676
Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D0Angelo A, Pengo V,
Erba N, Moia M, Ciavarella N, Devoto G, Berretini M, Musolesi S
(1996) Hemorrhagic complications of oral anticoagulant treatment: an
inception-cohort, prospective collaborative study (ISCOAT). Italian
Study on Complications of Oral Anticoagulant Therapy. Lancet
348(9025): 423–428
Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V,
Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III
Trial of cisplatin plus gemcitabine with either placebo or bevacizumab as
first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL.
J Clin Oncol 27: 1227–1234
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena D, Ou S, Taylor J,
Tanguay S, Dutcher J, Small EJ (2008) CALGB 90206: a phase III trial of
bevacizumab plus interferon-alpha versus interferon-alpha mono-
therapy in metastatic renal cell carcinoma. Genitourinary Cancers
Symposium 350: 2137–2143
Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S,
Lichinitser M, Yang TS, Rivera F, Couture F, Sirze ´n F, Cassidy J (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as
first-line therapy in metastatic colorectal cancer: a randomized phase III
study. J Clin Oncol 26(12): 2013–2019
S a n d l e rA ,G r a yR ,P e r r yM C ,B r a h m e rJ ,S c h i l l e rJ H ,D o w l a t iA ,L i l e n b a u mR ,
Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for
non-small-cell lung cancer. NE n g lJM e d355(24): 2542–2550
Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L,
McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000)
Common toxicity criteria: version 2.0. An improved reference for
grading the acute effects of cancer treatment: impact on radiotherapy.
Int J Radiat Oncol Biol Phys 47(1): 13–47
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C,
Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0:
development of a comprehensive grading system for the adverse effects
of cancer treatment. Semin Radiat Oncol 13(3): 176–181
Vredenburgh JJ, Desjardins A, Herndon II JE, Marcello J, Reardon DA,
Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC,
Watral MA, Krauser JM, Friedman AH, Friedman HS (2007) Bevacizu-
mab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol
25(30): 4722–4729
Bevacizumab safety in patients on full-dose anticoagulation
N Leighl et al
418
British Journal of Cancer (2011) 104(3), 413–418 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s